The Economics of Malaria Vaccine Development

Research output: Contribution to journalComment / DebateOtherpeer-review

Abstract

Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

Original languageEnglish
Pages (from-to)154-156
Number of pages3
JournalTrends in Parasitology
Volume33
Issue number3
DOIs
Publication statusPublished - 1 Mar 2017

Cite this

@article{a54d2f2491bb406282472ba04b970d1e,
title = "The Economics of Malaria Vaccine Development",
abstract = "Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).",
author = "Magdalena Plebanski and Flanagan, {Katie L.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1016/j.pt.2017.01.006",
language = "English",
volume = "33",
pages = "154--156",
journal = "Trends in Parasitology",
issn = "1471-4922",
publisher = "Elsevier",
number = "3",

}

The Economics of Malaria Vaccine Development. / Plebanski, Magdalena; Flanagan, Katie L.

In: Trends in Parasitology, Vol. 33, No. 3, 01.03.2017, p. 154-156.

Research output: Contribution to journalComment / DebateOtherpeer-review

TY - JOUR

T1 - The Economics of Malaria Vaccine Development

AU - Plebanski, Magdalena

AU - Flanagan, Katie L.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

AB - Vaccines that do not take a comprehensive endpoint view of the pathogen population they want to tackle early in their developmental process, may find it financially prohibitive to redesign them once they have progressed down a costly regulatory and human trial pathway. Specifically, the lead malaria vaccine candidate RTS,S has limited ability to tackle parasite polymorphism and may induce sex-specific nonspecific effects (NSEs).

UR - http://www.scopus.com/inward/record.url?scp=85011416633&partnerID=8YFLogxK

U2 - 10.1016/j.pt.2017.01.006

DO - 10.1016/j.pt.2017.01.006

M3 - Comment / Debate

VL - 33

SP - 154

EP - 156

JO - Trends in Parasitology

JF - Trends in Parasitology

SN - 1471-4922

IS - 3

ER -